enVVeno Medical Corporation (NASDAQ:NVNO) released its full‑year 2025 financial results, showing a net loss of $19.5 million—an improvement from the $21.8 million loss reported for 2024. The company’s revenue remained at zero, reflecting its continued focus on product development rather than commercialization.
The company reported research and development expenses of $10.0 million, a 19% decline from the previous year, and selling, general and administrative expenses of $10.9 million. Cash and investments totaled $28.2 million as of December 31, 2025, providing an operating runway into mid‑2027 even as cash burn is expected to rise to $4–5 million per quarter in 2026 to support the pivotal trial of its enVVe System.
enVVeno’s strategic pivot from the VenoValve to the enVVe System follows a “not‑approvable” letter from the FDA. The company now concentrates on a transcatheter, non‑surgical valve that could address a large unmet need in severe chronic venous insufficiency, a condition affecting an estimated 3.5 million U.S. patients with no approved replacement valves.
CEO Robert Berman said the company’s 2025 results “represent a significant inflection point.” He noted that after the regulatory setback, the firm accelerated development of the enVVe System, completed pre‑clinical work, and is preparing to launch a pivotal trial in 2026. Berman added that the system “represents a transformative opportunity to address a large and underserved patient population.”
The company’s guidance for 2026 indicates a cash burn of $4–5 million per quarter, consistent with the capital requirements of the upcoming trial. With $28.2 million in cash and investments, enVVeno expects to sustain operations through mid‑2027, underscoring the importance of the trial’s outcome for future revenue generation.
The results highlight the company’s continued investment in R&D and its strategic focus on a potentially high‑impact product, while the narrowing loss and solid cash position provide a foundation for the next phase of development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.